Aligos Therapeutics, Inc. (ALGS)
6.94
-0.15
(-2.12%)
USD |
NASDAQ |
Feb 25, 16:00
6.90
-0.04
(-0.58%)
After-Hours: 20:00
Aligos Therapeutics Cash from Investing (Quarterly) : 47.68M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -4.485B |
| ACADIA Pharmaceuticals, Inc. | -79.35M |
| Agenus, Inc. | 0.076M |
| Alnylam Pharmaceuticals, Inc. | -37.17M |
| Savara, Inc. | 21.47M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -24.34M |
| Cash from Financing (Quarterly) | -0.053M |
| Free Cash Flow | -79.53M |
| Free Cash Flow Per Share (Quarterly) | -2.366 |
| Free Cash Flow to Equity (Quarterly) | -23.72M |
| Free Cash Flow to Firm (Quarterly) | -24.54M |
| Free Cash Flow Yield | -128.4% |